Benzinga | Jul 13, 2020 04:33PM EDT

ProQR To Host 'Expert Perspectives' Call On LCA10 And Sepofarsen Jul. 20

Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Company will host an Expert Perspectives call on July 20, 2020 at 5:00 pm EDT, which will focus on Leber congenital amaurosis 10 (LCA10) and the investigational RNA therapy for LCA10, sepofarsen experience to date.

The call will include a snapshot from the ongoing InSight Phase 1/2 extension study of sepofarsen, including new preliminary data on second eye treatment. Participation in this extension study was offered to patients who completed their participation in the Phase 1/2 study of sepofarsen.

The call will feature a presentation by Aniz Girach, MD, Chief Medical Officer of ProQR Therapeutics. Dr. Girach will then discuss the interpretation of the data with Ian M. MacDonald MSc, MD, CM, Professor Emeritus in the Department of Ophthalmology and Visual Sciences, University of Alberta. They will review topics related to the extension trial data, as well as key takeaways in relation to the overall sepofarsen experience to date.

Event Details

Date/Time: July 20, 2020, 5:00-6:00 pm EDT

To register please follow this link.